ICER Releases Draft Evidence Report for AstraZeneca’s Asthma Drug

The Institute for Clinical and Economic Review (ICER) recently published its draft evidence report for asthma drug tezepelumab. The monoclonal antibody, developed by AstraZeneca and Amgen, received mixed reviews, largely due to modest cost-effectiveness results and insufficient diversity in clinical trial enrollees.

“According to ICER findings, treatment with tezepelumab results in gains of 1.09 quality-adjusted life years (QALY) and 1.12 equal value life years (evLYs). From a health system perspective and using a placeholder price of about $27,860 per year, reviewers estimated a cost of $430,000 per QALY gained and $422,000 per evLY gained, which would exceed usual cost-effectiveness thresholds.” Read more here.

(Source: Denise Myshko, Managed Healthcare Executive, 9/17/21)